Jocelyn Gilmartin

Statistics

Publications

Citations

190

H-Index

Active since

2005

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Belgium)

Jocelyn Gilmartin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacokinetics, clinical pharmacology, and pharmacology.

Publications per year

2005–2018

Publications

Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects

Matt S. Anderson, Jocelyn Gilmartin, Caroline Cilissen et al. · Antiviral Therapy · 2014 · 78 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals

Dirk Schürmann, Christian Sobotha, Jocelyn Gilmartin et al. · AIDS · 2015 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Context-dependent neuronal differentiation and germ layer induction of Smad4−/− and Cripto−/− embryonic stem cells

Kai‐Christian Sonntag, Rabi Simantov, Lars Björklund et al. · Molecular and Cellular Neuroscience · 2005 · 42 citations

Life Sciences, Cell Biology, Developmental Biology +16

A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes

Iain P. Fraser, Naomi D Neufeld, Larry A. Fox et al. · Pediatric Diabetes · 2018 · 16 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

No Meaningful Drug Interactions with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Coadministration

Matt S. Anderson, Jocelyn Gilmartin, Fan Li et al. · Antiviral Therapy · 2018 · 11 citations

Medicine, Pharmacokinetics, Pharmacology +17

1–5 of 5